纤维化标志物PRO-C3在晚期肝纤维化中更高,并在接受减重手术的患者中改善
在158例减重手术患者中,PRO-C3最高四分位者晚期肝纤维化(F3-4期)风险高于最低四分位(OR 5.8,95%CI 1.5-29.9,P=0.017),PRO-C3与胰岛素抵抗及肝酶正相关。63例随访患者术后3和12个月PRO-C3在基线高肝纤维化者中下降,且与代谢及肝脏指标改善相关;PRO-C6与肝纤维化分期无关,脂肪组织纤维化与两标志物均不相关。
要点
- PRO-C3最高四分位者晚期肝纤维化(F3-4期)风险是最低四分位的5.8倍。
- 减重术后PRO-C3在基线高肝纤维化患者中下降,与代谢及肝脏指标改善相关。
- PRO-C6与肝纤维化分期无关,脂肪组织纤维化不影响PRO-C3或PRO-C6水平。
核心结论
- PRO-C3与重度肥胖患者的晚期肝纤维化相关,减重术后下降,且不受脂肪组织纤维化影响;这些数据提示减重手术显著消除了非酒精性脂肪性肝病中肝纤维化的驱动因素。
研究设计与样本
- 在158例减重手术患者中测量血清PRO-C3和PRO-C6,并与术中获取的肝脏、皮下及大网膜脂肪组织组织学进行比较。
- 对63例患者在减重术后3个月和12个月随访时测定PRO-C3和PRO-C6水平。
主要发现
- PRO-C3最高四分位患者相比最低四分位,晚期肝纤维化(F3-4期)风险更高(比值比5.8;95%CI [1.5-29.9];P=0.017),校正年龄、性别和BMI。
- PRO-C3与胰岛素抵抗标志物和肝酶呈正相关。
- 减重术后,基线肝纤维化高的患者PRO-C3水平下降,该下降与代谢和肝脏参数改善相关。
- PRO-C6与肝纤维化分期无关。
- 脂肪组织纤维化在基线或减重术后均与PRO-C3或PRO-C6水平不相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
CONTEXT: Serum propeptides of type III and type VI collagen (PRO-C3 and PRO-C6) are elevated in advanced nonalcoholic fatty liver disease (NAFLD), but their value in patients with severe obesity and their evolution after bariatric surgery (BS) is unknown. It is unclear if these markers of fibrogenesis are affected by adipose tissue fibrosis (ATF). OBJECTIVE: We studied the association of PRO-C3 and PRO-C6 with liver fibrosis before BS, examined their evolution after BS, and evaluated how much patients' ATF contribute to their levels. METHODS: Serum PRO-C3 and PRO-C6 were measured in 158 BS patients and compared with liver, subcutaneous, and omental adipose tissue histology obtained during surgery. PRO-C3 and PRO-C6 levels of 63 patients were determined in follow-up at 3 and 12 months post-BS. RESULTS: Patients in the highest quartile of PRO-C3 had a higher risk of advanced liver fibrosis (stage F3-4; odds ratio 5.8; 95% CI [1.5-29.9]; P = 0.017) vs the lowest quartile (adjustment for age, gender, and BMI). PRO-C3 was positively correlated with markers of insulin resistance and liver enzymes. After BS, PRO-C3 levels decreased in patients with high baseline liver fibrosis. This decrease correlated with improvement of metabolic and liver parameters. PRO-C6 was not related to stage of liver fibrosis. ATF did not correlate with PRO-C3 or PRO-C6 levels at baseline or after BS. CONCLUSION: PRO-C3 was associated with advanced liver fibrosis in patients with severe obesity, and decreased after BS, without being affected by ATF. These data suggest that BS prominently eliminates drivers of hepatic fibrogenesis in NAFLD.
引用
- Bel Lassen P, Nori N, Bedossa P, et al. Fibrogenesis Marker PRO-C3 Is Higher in Advanced Liver Fibrosis and Improves in Patients Undergoing Bariatric Surgery. J Clin Endocrinol Metab. 2022. PMID: 34905051. doi:10.1210/clinem/dgab897
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。